Furthermore, a similar outcome was achieved by treatment with a specific small molecule NLRP3 inflammasome inhibitor (MCC950; detailed below in Section 6.1) that blocked NLRP3 activation in kidney DC, reduced IL-1β and IL-18 production and inhibited the progression of renal fibrosis [20]. Here, NLRP3 is linked to renal fibrosis.